Literature DB >> 33722896

Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma.

Eliana Marostica1, Rebecca Barber1,2, Thomas Denize3, Isaac S Kohane1, Sabina Signoretti3, Jeffrey A Golden3,4, Kun-Hsing Yu5,3.   

Abstract

PURPOSE: Histopathology evaluation is the gold standard for diagnosing clear cell (ccRCC), papillary, and chromophobe renal cell carcinoma (RCC). However, interrater variability has been reported, and the whole-slide histopathology images likely contain underutilized biological signals predictive of genomic profiles. EXPERIMENTAL
DESIGN: To address this knowledge gap, we obtained whole-slide histopathology images and demographic, genomic, and clinical data from The Cancer Genome Atlas, the Clinical Proteomic Tumor Analysis Consortium, and Brigham and Women's Hospital (Boston, MA) to develop computational methods for integrating data analyses. Leveraging these large and diverse datasets, we developed fully automated convolutional neural networks to diagnose renal cancers and connect quantitative pathology patterns with patients' genomic profiles and prognoses.
RESULTS: Our deep convolutional neural networks successfully detected malignancy (AUC in the independent validation cohort: 0.964-0.985), diagnosed RCC histologic subtypes (independent validation AUCs of the best models: 0.953-0.993), and predicted stage I ccRCC patients' survival outcomes (log-rank test P = 0.02). Our machine learning approaches further identified histopathology image features indicative of copy-number alterations (AUC > 0.7 in multiple genes in patients with ccRCC) and tumor mutation burden.
CONCLUSIONS: Our results suggest that convolutional neural networks can extract histologic signals predictive of patients' diagnoses, prognoses, and genomic variations of clinical importance. Our approaches can systematically identify previously unknown relations among diverse data modalities. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33722896     DOI: 10.1158/1078-0432.CCR-20-4119

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning.

Authors:  Paul H Acosta; Vandana Panwar; Vipul Jarmale; Alana Christie; Jay Jasti; Vitaly Margulis; Dinesh Rakheja; John Cheville; Bradley C Leibovich; Alexander Parker; James Brugarolas; Payal Kapur; Satwik Rajaram
Journal:  Cancer Res       Date:  2022-08-03       Impact factor: 13.312

2.  A Novel Radiogenomics Biomarker Based on Hypoxic-Gene Subset: Accurate Survival and Prognostic Prediction of Renal Clear Cell Carcinoma.

Authors:  Jiahao Gao; Fangdie Ye; Fang Han; Xiaoshuang Wang; Haowen Jiang; Jiawen Zhang
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

3.  Integrative multiomics-histopathology analysis for breast cancer classification.

Authors:  Yasha Ektefaie; William Yuan; Deborah A Dillon; Nancy U Lin; Jeffrey A Golden; Isaac S Kohane; Kun-Hsing Yu
Journal:  NPJ Breast Cancer       Date:  2021-11-29

4.  Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report.

Authors:  Xiaojun Ye; Xiangliang Liu; Na Yin; Wei Song; Jin Lu; Yi Yang; Xiao Chen
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

5.  IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy.

Authors:  Dafei Chai; Shang Yuchen Shi; Navid Sobhani; Jiage Ding; Zichun Zhang; Nan Jiang; Gang Wang; Minle Li; Hailong Li; Junnian Zheng; Jin Bai
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

6.  Deep learning can predict survival directly from histology in clear cell renal cell carcinoma.

Authors:  Frederik Wessels; Max Schmitt; Eva Krieghoff-Henning; Jakob N Kather; Malin Nientiedt; Maximilian C Kriegmair; Thomas S Worst; Manuel Neuberger; Matthias Steeg; Zoran V Popovic; Timo Gaiser; Christof von Kalle; Jochen S Utikal; Stefan Fröhling; Maurice S Michel; Philipp Nuhn; Titus J Brinker
Journal:  PLoS One       Date:  2022-08-17       Impact factor: 3.752

7.  Low LINC02147 expression promotes the malignant progression of oral submucous fibrosis.

Authors:  Jun Chen; Wenjie Li; Binjie Liu; Xiaoli Xie
Journal:  BMC Oral Health       Date:  2022-07-29       Impact factor: 3.747

8.  A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.

Authors:  Florian A Büttner; Stefan Winter; Jens Bedke; Matthias Schwab; Elke Schaeffeler; Viktoria Stühler; Steffen Rausch; Jörg Hennenlotter; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Marieta Toma; Carmen Jerónimo; Rui Henrique; Vera Miranda-Gonçalves; Nils Kröger; Silvia Ribback; Arndt Hartmann; Abbas Agaimy; Christine Stöhr; Iris Polifka; Falko Fend; Marcus Scharpf; Eva Comperat; Gabriel Wasinger; Holger Moch; Arnulf Stenzl; Marco Gerlinger
Journal:  Genome Med       Date:  2022-09-15       Impact factor: 15.266

Review 9.  Artificial Intelligence-Assisted Renal Pathology: Advances and Prospects.

Authors:  Yiqin Wang; Qiong Wen; Luhua Jin; Wei Chen
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

10.  BCNet: A Novel Network for Blood Cell Classification.

Authors:  Ziquan Zhu; Siyuan Lu; Shui-Hua Wang; Juan Manuel Górriz; Yu-Dong Zhang
Journal:  Front Cell Dev Biol       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.